Table 1.
Characteristics of musculoskeletal and connective tissue disorders reports for fluoroquinolones.
| Number of reports N = 5355, n (%) | n (%) | ||
|---|---|---|---|
| Sex | Reporter* | n = 5512 (100.00) | |
| Male | 1957 (36.54) | HCP | 1428 (25.91) |
| Female | 3307 (61.76) | Consumer | 2535 (45.99) |
| Unknown | 91 (1.70) | Other | 35 (0.63) |
| Unknown | 1514 (27.47) | ||
| Age, years | ADR† | n = 13,563 (100.00) | |
| < 18 | 51 (0.95) | Arthralgia | 2216 (16.34) |
| 18–64 | 3356 (62.67) | Tendonitis | 1498 (11.04) |
| ≥ 65 | 1251 (23.36) | Pain in extremity | 1353 (9.98) |
| Unknown | 697 (13.02) | Tendon pain | 1035 (7.63) |
| UN Continent | Myalgia | 973 (7.17) | |
| America | 3974 (74.21) | Tendon disorder | 776 (5.72) |
| Europe | 1350 (25.21) | Muscular weakness | 541 (3.99) |
| Asia | 22 (0.41) | Musculoskeletal pain | 479 (3.53) |
| Africa | 6 (0.11) | Muscle spasms | 438 (3.23) |
| Oceania | 3 (0.06) | Back pain | 358 (2.64) |
| Reporting years | FQ suspect‡ | n = 5558 (100.00) | |
| 1987–1994 | 32 (0.60) | Levofloxacin | 2781 (50.04) |
| 1995–1999 | 60 (1.12) | Ciprofloxacin | 2135 (38.41) |
| 2000–2004 | 427 (7.97) | Moxifloxacin | 287 (5.16) |
| 2005–2009 | 755 (14.10) | Ofloxacin | 176 (3.17) |
| 2010–2014 | 1296 (24.20) | Norfloxacin | 56 (1.01) |
| 2015–2019 | 2785 (52.01) |
FQ fluoroquinolone; HCP healthcare professional; N total number of reports; n: number of reports in a given category; UN Continent: Continent of the primary source, according to the United nations.
*More than one reporter could be mentioned per individual case;
†More than one ADR could be reported per individual case; Data presented for the first 10 ADRs.
‡More than one FQ could be reported per individual case; Data presented for the first 5 FQs.